Inspire Investing LLC Has $988,000 Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Inspire Investing LLC trimmed its holdings in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 18.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,972 shares of the company’s stock after selling 3,030 shares during the period. Inspire Investing LLC’s holdings in Dr. Reddy’s Laboratories were worth $988,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of RDY. Trexquant Investment LP bought a new position in shares of Dr. Reddy’s Laboratories during the 4th quarter worth about $219,000. Assetmark Inc. grew its stake in Dr. Reddy’s Laboratories by 3.2% in the fourth quarter. Assetmark Inc. now owns 47,711 shares of the company’s stock valued at $3,320,000 after acquiring an additional 1,479 shares during the period. Team Hewins LLC acquired a new stake in Dr. Reddy’s Laboratories in the fourth quarter valued at approximately $239,000. Orion Portfolio Solutions LLC increased its holdings in shares of Dr. Reddy’s Laboratories by 89.1% during the fourth quarter. Orion Portfolio Solutions LLC now owns 14,532 shares of the company’s stock valued at $1,015,000 after acquiring an additional 6,846 shares in the last quarter. Finally, Parallel Advisors LLC raised its position in shares of Dr. Reddy’s Laboratories by 6.1% during the fourth quarter. Parallel Advisors LLC now owns 6,514 shares of the company’s stock worth $453,000 after purchasing an additional 377 shares during the period. Institutional investors and hedge funds own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Trading Up 0.2 %

RDY opened at $78.52 on Friday. The firm has a market capitalization of $13.10 billion, a PE ratio of 19.48, a P/E/G ratio of 1.74 and a beta of 0.55. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.55 and a quick ratio of 1.90. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $63.72 and a fifty-two week high of $84.46. The company’s 50-day moving average is $81.16 and its 200 day moving average is $75.72.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings data on Saturday, July 27th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.10 by ($0.10). The company had revenue of $919.80 million during the quarter, compared to analysts’ expectations of $861.68 million. Dr. Reddy’s Laboratories had a return on equity of 20.32% and a net margin of 19.28%. As a group, research analysts predict that Dr. Reddy’s Laboratories Limited will post 4.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Barclays lifted their price target on shares of Dr. Reddy’s Laboratories from $81.00 to $87.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.